Associated Papers
Clinical Outcomes of Patients With Advanced ALK-Rearranged Lung Squamous Cell Carcinoma Treated With ALK Tyrosine Kinase Inhibitors.
Sun Y et al.
Clinical Lung Cancer, 2025
MET and NF2 alterations confer primary and early resistance to first-line alectinib treatment in ALK-positive non-small-cell lung cancer.
Hu J et al.
Molecular Oncology, 2025
Presence of On-Target Resistant Mutation in Pre-Treatment Samples of ALK Fusion Gene Positive Lung Cancer Patients.
Li W et al.
Cancers, 2025
Case Report: Metastatic colorectal cancer with ALK-CEP44 fusion and rapid resistance development.
Hofmann S et al.
Frontiers in Oncology, 2025
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.
Lin JJ et al.
Cancer Discovery, 2024
Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapy.
de Jager VD et al.
Esmo Open, 2024
Pathway-based, reaction-specific annotation of disease variants for elucidation of molecular phenotypes.
Orlic-Milacic M et al.
Database : the Journal of Biological Databases and Curation, 2024
Clinical utility of Next Generation Sequencing of plasma cell-free DNA for the molecular profiling of patients with NSCLC at diagnosis and disease progression.
Del Re M et al.
Translational Oncology, 2024
Somatic and germline ATM variants in non-small-cell lung cancer: Therapeutic implications.
Hernandez-Martinez JM et al.
Critical Reviews in Oncology/hematology, 2023
Gatekeeper mutations activate FGF receptor tyrosine kinases by destabilizing the autoinhibited state.
Besch A et al.
Proceedings of the National Academy of Sciences of the United States of America, 2023
Deciphering the Shared and Specific Drug Resistance Mechanisms of Anaplastic Lymphoma Kinase via Binding Free Energy Computation.
Yu Y et al.
Research (washington, D.c.), 2023
Identification of non-ATP-competitive α-carboline inhibitors of the anaplastic lymphoma kinase.
Mologni L et al.
European Journal of Medicinal Chemistry, 2022
Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer.
Shiba-Ishii A et al.
Nature Cancer, 2022
Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice.
Steeghs EMP et al.
Lung Cancer (amsterdam, Netherlands), 2022
Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis.
Angeles AK et al.
Npj Precision Oncology, 2021
Multi-Platform Classification of IDH-Wild-Type Glioblastoma Based on ERK/MAPK Pathway: Diagnostic, Prognostic and Therapeutic Implications.
Georgescu MM
Cancers, 2021
Sensitivity, specificity, and accuracy of a liquid biopsy approach utilizing molecular amplification pools.
Garcia J et al.
Scientific Reports, 2021
SPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA Genotyping.
Lawrence MN et al.
Jto Clinical and Research Reports, 2021
Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions.
Singh H et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2021
Novel Resistance Mechanisms Including L1196Q, P1094H, and R1248_D1249 Insertion in Three Patients With NSCLC After ALK Tyrosine Kinase Inhibitor Treatment.
Furuta H et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2021
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.
Mizuta H et al.
Nature Communications, 2021
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
Novel ALK mutation with durable response to brigatinib-a case report.
Latif H et al.
Translational Lung Cancer Research, 2020
Improvement in predicting drug sensitivity changes associated with protein mutations using a molecular dynamics based alchemical mutation method.
Ono F et al.
Scientific Reports, 2020
Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay.
Remon J et al.
Plos One, 2020
Efficacy and Resistance of ALK Inhibitors in Two Inflammatory Myofibroblastic Tumor Patients with ALK Fusions Assessed by Whole Exome and RNA Sequencing.
Zhang C et al.
Oncotargets and Therapy, 2020
Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity.
Dagogo-Jack I et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2019
Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.
Okada K et al.
Ebiomedicine, 2019
Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer.
Aggarwal C et al.
Jama Oncology, 2019
Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer.
Yu Y et al.
Lung Cancer (amsterdam, Netherlands), 2019
Computational analysis reveals histotype-dependent molecular profile and actionable mutation effects across cancers.
Heim D et al.
Genome Medicine, 2018
Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer.
McCoach CE et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2018
A Computational Approach for Prioritizing Selection of Therapies Targeting Drug Resistant Variation in Anaplastic Lymphoma Kinase.
McCoy MD et al.
Amia Joint Summits on Translational Science Proceedings. Amia Joint Summits on Translational Science, 2018
Receptor Tyrosine Kinases: Translocation Partners in Hematopoietic Disorders.
Nelson KN et al.
Trends in Molecular Medicine, 2017
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.
Mologni L et al.
Oncotarget, 2015
Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.
Zdzalik D et al.
Journal of Cancer Research and Clinical Oncology, 2014
Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors.
Ceccon M et al.
Molecular Cancer Research : Mcr, 2013